You are here
Ebola, Zika, and AR: Leveraging Diagnostics to Fight Emerging Infectious Disease Threats
Infectious diseases are constantly evolving, at a sometimes shocking pace. In recent years, the world has witnessed a combination of emerging microbes, resistant microbes that outsmart the drugs used to treat them, and the globalization of travel and trade. As we anticipate new and evolving global challenges in infectious disease, we need tools and technologies to address diverse threats, from the familiar to the new and emerging.
Advances in molecular sequencing and other innovations in diagnostics have helped public health professionals respond to the emerging and unexpected threats of Ebola and Zika. Now diagnostic manufacturers are focusing on the massive global health challenge of antibiotic resistance, which is a threat to every person and to modern medicine. Diagnostic tests can help clinicians decide whether an antibiotic will cure an infection and which specific drug will work best. This could dramatically reduce unnecessary antibiotic use and improve patient care.
Please join CDC and AdvaMedDx for a panel discussion on how diagnostic tests and molecular-based sequencing are responding to emerging infectious threats.
|View all images|
- Rima Khabbaz, MD, Deputy Director for Infectious Diseases and Director of the Office of Infectious Diseases, Centers for Disease Control and Prevention
- Kimberly Hanson, MD, MHS, Infectious Diseases Physician, University of Utah, Director of Clinical Microbiology, ARUP Laboratories, Infectious Diseases Society of America Diagnostics Committee Chair
- David Pincus, Research Fellow of Microbial Identification, bioMerieux
- Jill Taylor, Ph.D., Director, Wadsworth Center, New York State Department of Health
Lunch will be provided.